Ocular Therapeutix tumbles 18.8% on rival Kodiak's trial win
Kodiak Sciences' experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage wet AMD trial. RBC Capital Markets said the selloff in Ocular Therapeutics was overdone.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.